10-Q: Exela Technologies Reports Q3 2024 Results Amidst Delisting and Financial Challenges
Quarterly Report
Exela Technologies' Q3 2024 results show a revenue increase but also highlight ongoing financial difficulties, including a net loss and delisting from Nasdaq.
Summary
- Exela Technologies reported a revenue of $269.2 million for the third quarter of 2024, an increase of 6.3% compared to the same period last year.
- The company's net loss for the quarter was $24.9 million, slightly worse than the $23.1 million loss in Q3 2023.
- For the nine months ended September 30, 2024, revenue was $773.6 million, a decrease of 3.3% compared to the same period in 2023.
- The net loss for the first nine months of 2024 was $77.4 million, an improvement from the $99.4 million loss in the same period of 2023.
- The company's ITPS segment saw a revenue increase of 11.5% in Q3, while the HS segment experienced a 5.3% decrease and the LLPS segment saw a 2.4% decrease.
- Exela's accumulated deficit stood at $2,158.7 million as of September 30, 2024.
- The company's common stock was delisted from Nasdaq on November 8, 2024, and now trades on the OTC Pink market.
- Exela has a working capital deficit of $262.8 million as of September 30, 2024.
- The company has an obligation to make an interest payment of approximately $50 million on the April 2026 Notes due January 15, 2025.
Sentiment
Score: 2
Explanation: The document presents a very negative outlook due to the company's financial struggles, delisting, and going concern issues. While there are some positive aspects like revenue growth in ITPS, the overall sentiment is overwhelmingly negative.
Positives
- Exela's revenue increased by 6.3% in Q3 2024 compared to Q3 2023.
- The ITPS segment showed strong revenue growth of 11.5% in Q3 2024.
- The net loss for the first nine months of 2024 was $77.4 million, an improvement from the $99.4 million loss in the same period of 2023.
- The company is actively pursuing cost savings and exploring new financing options.
Negatives
- Exela experienced a net loss of $24.9 million in Q3 2024.
- The company's HS and LLPS segments saw revenue declines in Q3 2024.
- Exela's common stock was delisted from Nasdaq on November 8, 2024.
- The company has a substantial working capital deficit of $262.8 million.
- Exela has a significant interest payment of approximately $50 million due on January 15, 2025.
- The company has a large accumulated deficit of $2,158.7 million.
Risks
- Exela's ability to continue as a going concern is in substantial doubt due to a history of net losses, negative operating cash flow, and a large working capital deficit.
- The delisting from Nasdaq could negatively impact the company's ability to raise capital and the liquidity of its stock.
- The company faces significant debt obligations, including a $50 million interest payment due in January 2025.
- Exela's ability to execute its operational plans and obtain additional financing is uncertain.
- The company may need to consider restructuring if it cannot execute its plans.
- The company is subject to various legal proceedings, including a derivative action and an insurance claim dispute.
Future Outlook
The company plans to improve its available cash balances, liquidity, and cash generated from operations by completing cost savings, obtaining new financing, and/or restructuring existing debt facilities. However, the company's ability to execute these plans is uncertain.
Management Comments
- Management is focused on improving cash balances and liquidity.
- Management is exploring new financing options and restructuring existing debt.
- Management acknowledges the substantial doubt about the company's ability to continue as a going concern.
Industry Context
The document indicates that Exela is facing challenges common in the business process outsourcing industry, including the need to adapt to technological changes and manage large amounts of data. The company's delisting from Nasdaq and financial difficulties highlight the competitive pressures and risks in this sector.
Comparison to Industry Standards
- Exela's revenue growth in the ITPS segment is a positive sign, but the overall revenue decline and net losses are concerning compared to industry leaders.
- The company's high debt levels and working capital deficit are significantly worse than many of its competitors.
- The delisting from Nasdaq is a major setback and is not typical for established companies in the BPO sector.
- The company's reliance on debt financing and the need for restructuring are indicative of financial distress, which is not a common trait among successful BPO firms.
- Compared to companies like Accenture, Infosys, and Wipro, which have strong balance sheets and consistent profitability, Exela's financial performance is significantly weaker.
- The company's challenges are more akin to those of distressed companies rather than industry benchmarks.
Legal Proceedings
- The company is involved in a shareholder derivative action.
- The company is involved in an insurance claim dispute related to a network security incident.
- The SEC Staff informed the Company that they intend to open an investigation concerning the previously disclosed network outage that the Company experienced in the summer of 2022.
Related Party Transactions
- The company has various related-party transactions with entities affiliated with HandsOn Global Management LLC, including marketing fees, technology licensing, and facility leases.
- The company sold $3.0 million face value of April 2026 Notes for a net sale consideration of $0.5 million to affiliates of the Executive Chairman.
- The company entered into a Promissory Note Transfer Agreement with General Pacific LLC, an affiliate managed by HGM.
Stakeholder Impact
- Shareholders are negatively impacted by the delisting from Nasdaq and the decline in stock value.
- Employees face uncertainty due to the company's financial instability and potential restructuring.
- Customers may be concerned about the company's ability to provide consistent services.
- Creditors face increased risk due to the company's high debt levels and going concern issues.
- Suppliers may be concerned about the company's ability to pay its obligations.
Next Steps
- The company plans to complete cost savings initiatives.
- The company plans to obtain new financing capital and/or refinance or restructure existing debt facilities.
- The company will continue to pursue the sale of certain non-core businesses.
- The company will continue to respond to the SEC investigation.
Key Dates
| Date | Description |
|---|---|
| January 17, 2018 | Exela's 2018 Stock Incentive Plan became effective. |
| March 10, 2022 | Certificate of Designations for Series B Preferred Stock was dated. |
| May 17, 2022 | The Company issued one share of Tandem Preferred Stock as a dividend on its existing shares of outstanding Series B Preferred Stock. |
| June 17, 2022 | The Company entered into an amended and restated receivables purchase agreement. |
| August 10, 2022 | The Board authorized a share buyback program. |
| October 9, 2022 | The Company entered into a definitive merger agreement to merge its European business with CF Acquisition Corp. VIII. |
| February 27, 2023 | The SPEs and B. Riley Commercial Capital, LLC entered into a new Secured Promissory Note. |
| June 8, 2023 | The Company completed the sale of its high-speed scanner business. |
| July 11, 2023 | The Issuers issued approximately $767.8 million aggregate principal amount of the April 2026 Notes. |
| September 1, 2023 | The Company entered into a Master Services Agreement with Doctors of Waikiki LLP. |
| November 29, 2023 | The Company completed the merger of its European business with CF Acquisition Corp. VIII. |
| February 12, 2024 | Certain of the Company's subsidiaries entered into a receivables purchase agreement with BR Exar, LLC. |
| June 13, 2024 | Exela's 2024 Stock Incentive Plan became effective. |
| July 1, 2024 | The Company announced that its Board had authorized the Company to consider a spin-off of its wholly-owned subsidiary Exela Technologies BPA, LLC. |
| September 30, 2024 | The Company, through one of its subsidiaries, sold $3.0 million face value of April 2026 Notes for a net sale consideration of $0.5 million to affiliates of the Executive Chairman. |
| October 7, 2024 | The Company refunded $2.5 million of the First Note Transfer Purchase Price. |
| October 8, 2024 | The Company moved to amend the complaint to add two additional excess-layer insurers to the Insurance Lawsuit. |
| October 15, 2024 | The Company settled its claim against the other Second Excess Insurers for $3.6 million (less amounts already paid). |
| October 24, 2024 | The Amended Complaint was filed. |
| October 31, 2024 | The Company entered into a Promissory Note Transfer Agreement with General Pacific. |
| November 1, 2024 | The deadline set by the Nasdaq Hearings Panel for the Company to regain compliance. |
| November 4, 2024 | General Pacific elected to purchase $0 face value of April 2026 Notes for a net sale consideration of $0 under the Second Note Transfer Agreement. |
| November 6, 2024 | Nasdaq notified the Company that the Panel had determined to delist the Company's common stock. |
| November 8, 2024 | Exela's common stock and Series B Preferred Stock began trading on the OTC Pink market. |
| November 12, 2024 | A special committee of independent members of the Company's Board of Directors approved a negotiated share exchange. |
| November 14, 2024 | The date of this report. |
Keywords
Exela Technologies, financial results, Q3 2024, delisting, Nasdaq, OTC Pink, net loss, revenue, debt, going concern, working capital, ITPS, HS, LLPS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.